Incidence and outcomes of neonatal acute kidney injury (AWAKEN): a multicentre, multinational, observational cohort study

Jennifer G Jetton, Louis J Boehraker, Sidarth K Sethi, Sanjay Wazir, Smriti Rohatgi, Danielle E Saranno, Aftab S Chishti, Robert Woroniecki, Cherry Mammen, Jonathan R Swanson, Shanthy Sridhar, Craig S Wong, Ivan C Kupferman, Russell L Griffin, David J Askenazi, on behalf of the Neonatal Kidney Collaborative (NKC)

Summary

Background Findings from single-centre studies suggest that neonatal acute kidney injury (AKI) is associated with poor outcomes. However, because of the small sample size of those studies, few inferences can be made regarding the independent associations between AKI, mortality, and hospital length of stay. We aimed to establish whether neonatal AKI is independently associated with increased mortality and length of hospital stay.

Methods We did this multicentre, multinational, retrospective cohort study of critically ill neonates admitted to 24 participating neonatal intensive care units (NICUs) in four countries (Australia, Canada, India, USA) between Jan 1 and March 31, 2014. We included infants born or admitted to a level 2 or 3 NICU and those who received intravenous fluids for at least 48 h. Exclusion criteria were admission at age 14 days or older, congenital heart disease requiring surgical repair within 7 days of life, lethal chromosomal anomaly, death within 48 h of admission, inability to determine AKI status, or severe congenital kidney abnormalities. We defined AKI as an increase in serum creatinine of ≥0·3 mg/dL or more (≥26·5 µmol/L) or 50% or more from the previous lowest value, or a urinary output of less than 1 mL/kg per h on postnatal days 2–7. We used logistic regression to calculate crude odds ratios (ORs) and associated 95% CIs for the association between AKI and likelihood of death. We used linear regression to calculate the crude parameter estimates and associated 95% CIs for the association between AKI and length of hospital stay. Multivariable logistic and linear regression models were run to account for potential confounding variables. We additionally created regression models stratified by gestational age groups (22 weeks to <29 weeks, 29 weeks to <36 weeks, and ≥36 weeks). This study is registered with ClinicalTrials.gov, number NCT02443389.

Findings We enrolled 2162 infants, of whom 2022 (94%) had data to ascertain AKI status. 605 (30%) infants had AKI. Incidence of AKI varied by gestational age group, occurring in 131 (48%) of 273 of patients born at 22 weeks to less than 29 weeks, 168 (18%) of 916 patients born at 29 weeks to less than 36 weeks, and 306 (37%) of 833 patients born at 36 weeks or older. Infants with AKI had higher mortality than those without AKI (59 [10%] of 605 vs 20 [1%] of 1417 infants; p<0·0001), and longer length of hospital stay (median 23 days [IQR 10–61] vs 19 days [9–36]; p<0·0001). These findings were confirmed in both crude analysis of mortality (OR 7·5, 95% CI 4·5–12·7; p<0·0001 for AKI vs no AKI) and length of stay (parameter estimate 14·9 days, 95% CI 11·6–18·1; p<0·0001) and analysis adjusted for multiple confounding factors (adjusted OR 4·6, 95% CI 2·5–8·3; p<0·0001 and adjusted parameter estimate 8·8 days, 95% CI 6·1–11·5; p<0·0001, respectively).

Interpretation Neonatal AKI is a common and independent risk factor for mortality and increased length of hospital stay. These data suggest that AKI might have a similar effect in neonates as in paediatric and adult patients. Strategies designed to prevent AKI and treatments to reduce the burden of AKI, including renal support devices designed for neonates, are greatly needed to improve the outcomes of these vulnerable infants.

Funding US National Institutes of Health, University of Alabama at Birmingham, Cincinnati Children’s Hospital, University of New Mexico, Canberra Hospital Private Practice fund, and 100 Women Who Care.

Introduction

Study of acute kidney injury (AKI) in critically ill neonates has lagged behind that in older populations; however, the past 5 years have seen an intensification of research in this area. Findings from small, single-centre studies in neonates with congenital heart disease, sepsis, and hypoxic ischaemic injury; infants who receive extracorporeal membrane oxygenation; and infants of very low birthweight suggest that AKI is common and that neonates and children with AKI have worse outcomes than do those without the disorder. Although provocative, multicentre studies that use a contemporary definition and incorporate large sample sizes are needed to enable adjustment for multiple potential confounders and allow for generalisability. Moreover, studies that encompass the entire neonatal intensive care unit (NICU) population might offer comparative insights across different gestational age groups.
Research in context

Evidence before this study
We searched PubMed between Jan 1, 2006, and Dec 31, 2016, for studies of acute kidney injury (AKI) in neonates, with the search terms “neonatal”, “neonate”, “infant”, “kidney injury”, “acute kidney injury”, “renal failure”, “acute renal failure”. We reviewed the reference lists of each study obtained through PubMed to identify additional studies not previously detected. The multidisciplinary nature of the Neonatal Kidney Collaborative allowed for input from members familiar with both the neonatology and the paediatric nephrology literature. Studies identified included either retrospective or prospective observational data from single centres with small sample sizes. Most studies were limited to specific subsets of patients, such as very low birthweight infants, infants with perinatal asphyxia or sepsis, or infants receiving extracorporeal membrane oxygenation. Only one study included urinary output criteria in the definition of AKI; the rest used only serum creatinine-based definitions. Multiple different serum creatinine-based AKI definitions have been used, making data comparison across studies difficult. The incidence of neonatal AKI based on published studies ranges from 3% to 71%—a wide range that reflects heterogeneity in patient selection, frequency and type of monitoring, and the AKI definition used. Most studies show that AKI is associated with poor outcomes, but are limited by small sample size when controlling for potential confounders.

Added value of this study
To our knowledge, the Assessment of Worldwide Acute Kidney injury Epidemiology in Neonates (AWAKEN) study is the largest neonatal AKI study to date. It is the first multicentre, multinational project and the first to include infants admitted to the neonatal intensive care unit (NICU) across the gestational age spectrum, allowing us to make comparisons across gestational age groups. Our findings show that about 30% of sick neonates admitted to the NICU develop AKI, and that neonatal AKI is associated with morbidity and mortality independent of multiple potential confounders. Use of a standardised AKI definition modified from one that is widely accepted for use in paediatric and adult cohorts allows for comparison of our data to those from adult and paediatric intensive care unit populations. This study will help move the field forward toward the establishment of a common framework for neonatal AKI research.

Implications of all the available evidence
This work improves our understanding of the incidence of AKI in the NICU and its association with important clinical outcomes in these patients. AKI affects neonates of all gestational ages. Consistent with studies in other critically ill populations, neonatal AKI is not simply an incidental finding, but a key event that affects mortality and hospital length of stay. Future studies that capture AKI systematically during high-risk events are greatly needed. With AWAKEN as a foundation, additional studies will provide data needed to support the development of evidence-based monitoring guidelines for use by neonatologists, paediatricians, and paediatric nephrologists as they care for patients with AKI in the NICU and those at risk for chronic kidney disease in the future. Strategies designed to prevent AKI and treatments to reduce the burden of AKI, including renal support devices designed for neonates, are greatly needed to improve the outcomes of these vulnerable infants.

Methods

Study design and participants
We did the Assessment of Worldwide Acute Kidney injury Epidemiology in Neonates (AWAKEN) study to establish whether neonatal AKI is independently associated with increased mortality and length of hospital stay. We hypothesised that neonatal AKI would be associated with increased mortality and length of stay in the NICU, independent of demographics, comorbidities, and severity of illness.

Data collection
The variables extracted were chosen based on their relevance to the study of neonatal AKI. All data, including frequency of laboratory monitoring, reflect local standards of care and were dictated by the treating at age 14 days or older, congenital heart disease requiring surgical repair within 7 days of life, lethal chromosomal anomaly, death within 48 h of NICU admission, and severe congenital kidney and urinary tract abnormalities. We selected these criteria to enable enrolment of infants who were most likely to have measurements for serial serum creatinine and urinary output. Babies admitted to the NICU without need for intravenous fluids are generally only mildly ill (ie, transient tachypnoea of the newborn, transient hypoglycaemia, advancement of feeds) and receive intensive care for only a short period.

The institutional review board (IRB) of the University of Alabama at Birmingham approved this collaborative study, and each centre received approval from their respective IRBs. The study design allowed for a waiver of informed consent or parental permission.

We did this multicentre, multinational, retrospective cohort study of critically ill neonates from 24 centres participating in the Neonatal Kidney Collaborative (NKC) in Australia, Canada, India, and the USA. A complete description of the formation of the NKC and methods for development of the AWAKEN database have been published elsewhere.*

We reviewed medical records for all neonates admitted to level 2–4 NICUs between Jan 1 and March 31, 2014. We included neonates admitted within the study period and those who received intravenous fluids for at least 48 h. Exclusion criteria were admission at age 14 days or older, congenital heart disease requiring surgical repair within 7 days of life, lethal chromosomal anomaly, death within 48 h of NICU admission, and severe congenital kidney and urinary tract abnormalities. We selected these criteria to enable enrolment of infants who were most likely to have measurements for serial serum creatinine and urinary output. Babies admitted to the NICU without need for intravenous fluids are generally only mildly ill (ie, transient tachypnoea of the newborn, transient hypoglycaemia, advancement of feeds) and receive intensive care for only a short period.

The institutional review board (IRB) of the University of Alabama at Birmingham approved this collaborative study, and each centre received approval from their respective IRBs. The study design allowed for a waiver of informed consent or parental permission.

The variables extracted were chosen based on their relevance to the study of neonatal AKI. All data, including frequency of laboratory monitoring, reflect local standards of care and were dictated by the treating...
clinicians. All data were entered and stored in MediData RAVE (version 2014.2.0)—a web-based database. Detailed description of data collection for AWAKEN has been previously published. Briefly, we organised data into five components: baseline demographics, daily information for week 1, weekly snapshots for the remainder of the time in hospital, discharge data (captured at discharge or 120 days of age, whichever came first), and prolonged length-of-stay data for infants who were in hospital for longer than 120 days.

**Definition of acute kidney injury**

All serum creatinine values obtained during the study period were recorded. We defined AKI as an increase in serum creatinine of 0·3 mg/dL or more (≥26·5 μmol/L) or 50% or more from the previous lowest value, or a urinary output of less than 1 mL/kg per h on postnatal days 2–7, according to the Kidney Disease: Improving Global Outcomes (KDIGO) workgroup AKI definition modified for neonates, as used in previous neonatal studies (appendix). This definition differs from KDIGO in three ways. First, urinary output is reported in 24 h increments rather than in 6–12 h blocks, because most centres did not record urinary output on an hourly basis. Second, to classify a patient with serum creatinine-defined AKI, each measurement was compared with the lowest previous measurement to detect both an absolute and a percentage rise from baseline. Comparison with the lowest previous serum creatinine value is necessary because serum creatinine values normally decline over the first weeks after birth, such that the baseline value is constantly changing. Third, a serum creatinine cutoff of 2·5 mg/dL (221 µmol/L), rather than 4·0 mg/dL (353·6 µmol/L) as used in adults, was used for stage 3, since the cutoff of 2·5 mg/dL yields a glomerular filtration rate of less than 10 mL/min per 1·73 m².

When an infant had less than two serum creatinine measurements assessed during hospital admission, we deemed data insufficient for classification of serum creatinine-defined AKI. The urinary output threshold for AKI was set at 1 mL/kg per h or less averaged over 24 h on days 2–7 after birth. If an infant did not have at least 1 day with quantifiable urinary output in the medical record, we deemed data insufficient for classification of urinary output-defined AKI. Either diaper or catheter urine collection was acceptable as long as the urinary output was quantifiable. Infants were classified as having AKI if they met either the serum creatinine or urinary output definitions. The maximum AKI stage was classified as the highest of either serum creatinine or urinary output criteria. AKI severity was classified into one of three stages by use of traditional KDIGO methods (appendix).

**Severity of illness score**

We used the clinic risk index for babies II (CRIB II) score to assess severity of illness for infants in the 22 weeks or older to younger than 29 week cohort for gestational age. This risk adjustment tool for assessing the probability of mortality incorporates five variables: sex, birthweight, gestational age, temperature at admission (°C), and base excess (mmol/L). This scoring system was validated in infants with a gestational age of 32 weeks or younger; therefore, it was incorporated only into the models for the youngest gestational age cohort. No available, validated severity of illness scores are available for infants with a gestational age of 32 weeks or more.
for potential confounding variables, and findings are reported as adjusted OR and adjusted parameter estimate, respectively. Adjusted regression models were constructed with a backwards selection procedure with a significance level to stay of less than 0.2. Separate regression models were created for the whole cohort and cohorts stratified by gestational age groups (22 weeks to <29 weeks, 29 weeks to <36 weeks, and ≥36 weeks).

We did time-to-event analysis for survival by AKI status and maximum AKI stage with Kaplan–Meier analysis of the entire cohort and for each gestational age category. A p value of less than 0.05 was considered statistically significant.

The design of this study did not allow for standardised assessment of serum creatinine or urinary output values. We did a post-hoc sensitivity analysis of infants in whom AKI status could not be determined. To determine whether these missing data would have affected our results significantly, we did best-case and worst-case sensitivity analyses for the incidence of AKI, hospital survival, and hospital length of stay. Similarly, we did a post-hoc sensitivity analysis to determine differences between infants born at centres that measured serum creatinine more often (median five or more counts per infant) versus less often (less than five counts).

We did analyses with SAS (version 9.4). This study is registered with ClinicalTrials.gov, number NCT02443389.

Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. DA, LJB, and RLG had full access to all the data in the study. The corresponding author had final responsibility for the decision to submit for publication.

Results
We enrolled 2162 infants, of whom 2022 (94%) had data to ascertain AKI status and comprised the final sample (figure 1). Within the cohort stratified by gestational age group, 273 (14%) patients were 22 weeks to younger than 29 weeks old, 916 (45%) were 29 weeks to younger than 36 weeks, and 833 (41%) were 36 weeks or older (figure 2).

561 (28%) patients had fewer than two serum creatinine measurements and 243 (12%) patients had no quantifiable urinary output data for the first week of life (figure 3). Of these patients, 140 (7%) neonates had both fewer than two serum creatinine values and insufficient urinary output data, and therefore could not be given any AKI classification and were excluded from the analysis (figure 3). Of the remaining sample, 281 (14%) of 2022 patients had urinary output-defined AKI and 380 (19%) patients had serum creatinine-defined AKI (figure 3). Only 56 (3%) infants had AKI defined by both measurements (figure 3). 561 (28%) patients had fewer than two serum creatinine measurements and 243 (12%) patients had no quantifiable urinary output data for the first week of life (figure 3). Of these patients, 140 (7%) neonates had both fewer than two serum creatinine values and insufficient urinary output data, and therefore could not be given any AKI classification and were excluded from the analysis (figure 3). Of the remaining sample, 281 (14%) of 2022 patients had urinary output-defined AKI and 380 (19%) patients had serum creatinine-defined AKI (figure 3). Only 56 (3%) infants had AKI defined by both measurements (figure 3). 605 (30%) patients had fewer than two serum creatinine measurements and 243 (12%) patients had no quantifiable urinary output data for the first week of life (figure 3). Of these patients, 140 (7%) neonates had both fewer than two serum creatinine values and insufficient urinary output data, and therefore could not be given any AKI classification and were excluded from the analysis (figure 3). Of the remaining sample, 281 (14%) of 2022 patients had urinary output-defined AKI and 380 (19%) patients had serum creatinine-defined AKI (figure 3). Only 56 (3%) infants had AKI defined by both measurements (figure 3). 605 (30%) patients had fewer than two serum creatinine measurements and 243 (12%) patients had no quantifiable urinary output data for the first week of life (figure 3). Of these patients, 140 (7%) neonates had both fewer than two serum creatinine values and insufficient urinary output data, and therefore could not be given any AKI classification and were excluded from the analysis (figure 3). Of the remaining sample, 281 (14%) of 2022 patients had urinary output-defined AKI and 380 (19%) patients had serum creatinine-defined AKI (figure 3). Only 56 (3%) infants had AKI defined by both measurements (figure 3). 605 (30%) patients had fewer than two serum creatinine measurements and 243 (12%) patients had no quantifiable urinary output data for the first week of life (figure 3). Of these patients, 140 (7%) neonates had both fewer than two serum creatinine values and insufficient urinary output data, and therefore could not be given any AKI classification and were excluded from the analysis (figure 3). Of the remaining sample, 281 (14%) of 2022 patients had urinary output-defined AKI and 380 (19%) patients had serum creatinine-defined AKI (figure 3). Only 56 (3%) infants had AKI defined by both measurements (figure 3).
Table 1: Patients' characteristics

| Infant variables                  | No AKI  (n=1417) | AKI   (n=605) | p value |
|-----------------------------------|------------------|--------------|---------|
| Sex                               |                  |              |         |
| Female                            | 622 (44%)        | 258 (43%)    | 0.12    |
| Male                              | 795 (56%)        | 347 (57%)    |         |
| Ethnic origin                     |                  |              | 0.03    |
| Hispanic                          | 198 (14%)        | 60 (10%)     |         |
| Non-Hispanic                      | 1004 (71%)       | 441 (73%)    |         |
| Unknown                           | 215 (15%)        | 104 (17%)    |         |
| Race                              |                  |              | 0.07    |
| White                             | 777 (55%)        | 364 (58%)    |         |
| Black                             | 271 (19%)        | 107 (18%)    |         |
| Other                             | 369 (26%)        | 134 (22%)    |         |
| Site of delivery (outborn)        | 505 (36%)        | 349 (58%)    | <0.0001 |
| Gestational age                   |                  |              | <0.0001 |
| <22 weeks to <29 weeks            | 142 (10%)        | 131 (22%)    |         |
| 29 weeks to <36 weeks             | 748 (53%)        | 168 (28%)    |         |
| ≥36 weeks                         | 527 (37%)        | 306 (51%)    |         |
| Birthweight (g)                   |                  |              | <0.0001 |
| ≤1000                             | 112 (8%)         | 119 (20%)    |         |
| 1001-1500                         | 238 (17%)        | 57 (9%)      |         |
| 1501-2500                         | 552 (39%)        | 124 (21%)    |         |
| ≥2501                             | 513 (36%)        | 302 (50%)    |         |
| Apgar score                       |                  |              |         |
| 1 min                              | 7.00 (5.00–8.00) | 6.00 (3.00–8.00) | <0.0001 |
| 5 min                              | 8.00 (7.00–9.00) | 8.00 (6.00–9.00) | <0.0001 |
| Reason for admission*             |                  |              |         |
| Prematurity <35 weeks             | 792 (56%)        | 263 (43%)    | <0.0001 |
| Respiratory symptoms              | 314 (22%)        | 150 (25%)    | 0.20    |
| Respiratory failure               | 651 (46%)        | 281 (46%)    | 0.84    |
| Sepsis evaluation                 | 742 (52%)        | 274 (45%)    | 0.004   |
| Hypoxic ischaemic encephalopathy  | 70 (5%)          | 48 (8%)      | 0.01    |
| Seizures                          | 33 (2%)          | 37 (6%)      | <0.0001 |
| Hypoglycaemia                     | 168 (12%)        | 50 (8%)      | 0.02    |
| Hyperbilirubinemia                | 32 (2%)          | 29 (5%)      | 0.002   |
| Metabolic evaluation              | 8 (1%)           | 12 (2%)      | 0.003   |
| Trisomy 21                        | 14 (1%)          | 9 (1%)       | 0.33    |
| Congenital heart disease          | 34 (2%)          | 48 (8%)      | <0.0001 |
| Necrotising enterocolitis         | 6 (1%)           | 15 (2%)      | <0.0001 |
| Omphalocele and gastroschisis     | 32 (2%)          | 15 (2%)      | 0.76    |
| Need for surgical evaluation      | 47 (3%)          | 48 (8%)      | <0.0001 |
| Meningomyelocele                  | 9 (1%)           | 8 (1%)       | 0.12    |
| Small for gestational age         | 306 (22%)        | 117 (19%)    | 0.27    |
| Large for gestational age         | 58 (4%)          | 40 (7%)      | 0.02    |

(Continued from previous column)

| Maternal variables                | No AKI  (n=1417) | AKI   (n=605) | p value |
|-----------------------------------|------------------|--------------|---------|
| Age (years)                       | 28.6 (6.2)       | 28.3 (5.9)   | 0.24    |
| Infections                        |                  |              |         |
| Bacterial                         | 120 (8%)         | 66 (11%)     | 0.08    |
| Viral                             | 35 (2%)          | 23 (4%)      | 0.10    |
| Diabetes                          | 203 (14%)        | 68 (11%)     | 0.06    |
| Hypothyroidism                    | 64 (5%)          | 33 (5%)      | 0.37    |
| Chronic hypertension              | 140 (10%)        | 38 (6%)      | 0.01    |
| Kidney disease                    | 12 (1%)          | 6 (1%)       | 0.75    |
| Pre-eclampsia                     | 220 (16%)        | 67 (11%)     | 0.01    |
| Eclampsia                         | 17 (1%)          | 8 (1%)       | 0.82    |
| Intrauterine growth retardation   | 136 (10%)        | 52 (9%)      | 0.48    |
| Oligohydramnios                   | 65 (5%)          | 33 (5%)      | 0.41    |
| Polyhydramnios                    | 39 (3%)          | 34 (6%)      | 0.002   |
| Haemorrhage                       | 40 (3%)          | 23 (4%)      | 0.25    |
| Multiple gestation                | 291 (21%)        | 67 (13%)     | <0.0001 |
| Assisted conception               | 112 (8%)         | 37 (6%)      | 0.003   |
| Drugs used during pregnancy       |                  |              |         |
| Steroids                          | 563 (40%)        | 173 (29%)    | <0.0001 |
| ACE inhibitors                    | 0                | 0            | NA      |
| NSAIDs                            | 46 (3%)          | 16 (3%)      | 0.47    |
| Antihypertensives                 | 172 (12%)        | 44 (7%)      | 0.002   |
| Illicit drugs                     | 115 (8%)         | 40 (8%)      | 0.99    |
| Tobacco                           | 156 (11%)        | 64 (11%)     | 0.78    |
| Alcohol                           | 27 (2%)          | 9 (1%)       | 0.52    |
| SSRIs                             | 42 (3%)          | 17 (3%)      | 0.85    |
| Intrapartum complications         |                  |              |         |
| Nuchal cord                       | 85 (6%)          | 40 (7%)      | 0.60    |
| Meconium                          | 142 (10%)        | 74 (12%)     | 0.14    |
| Severe vaginal bleeding           | 58 (4%)          | 33 (5%)      | 0.18    |
| Shoulder dystocia                 | 13 (1%)          | 7 (1%)       | 0.62    |
| Disposition                       |                  |              | <0.0001 |
| Discharged within 120 days        | 1156 (82%)       | 400 (66%)    |         |
| Still in NICU at >120 days        | 28 (2%)          | 53 (9%)      |         |
| Transfer convalescent care        | 200 (14%)        | 73 (12%)     |         |
| Transfer escalated care           | 13 (1%)          | 20 (3%)      |         |
| Died in hospital                  | 20 (1%)          | 59 (10%)     |         |

Data are n (%), median (IQR), or n (%), unless otherwise specified. AKI=acute kidney injury. ACE=angiotensin-converting enzyme. NSAID=non-steroidal anti-inflammatory drug. SSRI=selective serotonin uptake inhibitors. NA=not applicable. NICU=neonatal intensive care unit. *Patients could have had more than one reason for admission.

of oligohydramnios and intrauterine growth restriction, or in infants’ sex (table 1). Mothers of infants with AKI were less likely to have chronic hypertension or pre-eclampsia, or to have received steroids or antihypertensives (table 1).
Maternal history of eclampsia, kidney disease, illicit drug exposure, and intrapartum complications did not differ significantly between groups (table 1).

Clinical care of critically ill neonates, and frequency of monitoring of kidney function, reflect local standards of care. The appendix provides a summary of serum creatinine counts, rates of AKI, country, type of serum creatinine assay, and mortality outcomes by centre. Median serum creatinine counts per patient varied from one (IQR one to one) to 11 (three to 26). Incidence of AKI by centre varied from 3% to 74%, with higher AKI rates noted in the centres with more serum creatinine counts, rates of AKI, country, type of serum creatinine assay, and mortality outcomes by centre. Survival rates varied from 78% to 100%, with only one US centre reporting a rate of less than 78%. AKI was significantly associated with increased mortality and hospital length of stay in both crude analysis and analysis adjusted for multiple demographic characteristics, interventions, and comorbidities (table 3). Survivors with AKI had longer length of stay than those without AKI (median 23 days [IQR 11–64] vs 19 days [9–36]; p<0.0001). Length of stay did not differ significantly between non-survivors with AKI and non-survivors without AKI (median 13 days [IQR 5–21] vs 15 [5–33]; p=0.38).

The appendix shows outcomes stratified by gestational age group. Evaluation of the gestational age groups showed that, after controlling for potential confounders, AKI status was independently associated with increased odds of death for the group born at 22 weeks to less than 29 weeks (adjusted OR 3.7, 95% CI 1.4–9.7), the group born at 29 weeks to less than 36 weeks (5.1, 1.6–16.5), and the group born at 36 weeks or older (3.9, 1.2–13.2; appendix). However, an association between AKI and length of stay was shown only in the two oldest gestational groups (29 weeks to <36 weeks: β parameter estimate 9.6, 95% CI 5.4–13.8; ≥36 weeks: 11.0, 8.0–14.0), but not in the youngest age group (0–5, −11.1 to 12.1; appendix).

Mortality in the 140 infants who could not be given an AKI classification because of insufficient data for serum creatinine or urinary output was similar to that in infants in the group with no AKI (four [3%] of 140 vs 20 [1%] of 1417 infants; p=0.18).

Most infants died within the first 50 days of hospital admission (figure 4). Survival was worse in infants with AKI than in those without AKI (figure 4). When stratified according to AKI stage, infants with stage 3 AKI had worse survival outcomes than those with stage 2 or stage 1 disorder, or those without AKI (figure 4). Notably, infants in the stage 1 group had worse survival than did those in the stage 2 group (p<0.0001; figure 4). Findings were similar when the survival curves were stratified by gestational age category (appendix).

In sensitivity analysis of the worst-case scenario (n=140 with missing data had AKI), 745 (34%) of 2162 infants had AKI. AKI was significantly associated with mortality (crude OR 6.4, 95% CI 3.9–10.7; p<0.0001) and hospital length of stay (crude parameter estimate 8.7 days, 95% CI 5.7–11.6; p<0.0001). After adjustment, infants with AKI had higher odds of death (adjusted OR 4.2,
95% CI 2·3–3·7; p=0·0001) and longer hospital length of stay (adjusted parameter estimate 5·3 days, 95% CI 2·9–7·8; p<0·0001) than did those with no AKI. In the best-case scenario (n=140 with missing data did not have AKI), 605 (28%) of 2162 infants did have AKI. AKI was significantly associated with mortality (crude OR 6·9, 95% CI 4·2–11·2; p<0·0001) and hospital length of stay (crude parameter estimate 16·5 days, 95% CI 13·4–19·6; p=0·0001). After adjustment, infants with AKI had higher odds of death (adjusted OR 3·6, 95% CI 2·0–6·2; p<0·0001) and longer hospital length of stay (adjusted parameter estimate 9·6 days, 95% CI 7·0–12·2; p<0·0001) than did those with AKI. This finding suggests that these patients with missing classification did not affect the overall findings.

As expected, incidence of AKI in the centres that measured serum creatinine often (median five or more counts per infant) was higher than the incidence of AKI in centres that measured serum creatinine less often (less than five counts per infant; 347 [41%] of 840 vs 258 [22%] of 182 infants; p<0·0001). Regardless of whether infants were in centres that checked serum creatinine often or not, infants with AKI had higher adjusted odds of death and length of stay than did infants without AKI. Specifically, in centres that did checks often, the adjusted OR for death was 3·1 (95% CI 1·3–7·4; p=0·01), and for length of stay was 13 (95% CI 8·2–17·7; p<0·0001); in centres that did checks less often, the adjusted ORs were 6·1 (95% CI 2·5–14·6; p<0·0001) and 4·4 (95% CI 1·2–7·7; p=0·01), respectively.

Renal replacement therapy (RRT) was done in 25 (4%) of 605 neonates with AKI, which accounts for 25 (1%) of 2022 neonates enrolled in the study and 25 (1%) of 4273 neonates admitted to the NICU during the 3 month period. Types of RRT included peritoneal dialysis alone (n=9), continuous RRT (n=4), continuous RRT plus extracorporeal membrane oxygenation (n=1), and peritoneal dialysis plus continuous RRT (n=1). No infants were dialysed with intermittent haemodialysis or sustained low-efficiency dialysis. Of infants who received RRT, 19 (76%) survived. Infants with AKI who had RRT had lower survival than those with AKI who did not have RRT (19 [76%] vs 527 [91%] of 580; p=0·01). Hospital length of stay was numerically, albeit not significantly, longer in infants with AKI who did not have RRT than in those who did have RRT (median 43 days [IQR 22–103] vs 22 days [10–61]; p=0·07).

Discussion
The overall incidence of AKI in neonates enrolled in the AWAKEN study was 30%, and infants with AKI had four times higher independent odds of death and longer independent hospital length of stay than those without AKI. These data support findings from studies of other critically ill neonates, children, and adults, which show that AKI is associated with poor outcomes, even after controlling for numerous confounders. The large sample size highlights practice variations in monitoring for neonatal AKI and shows differences in AKI incidence and outcomes across gestational age categories.

Although the overall incidence of AKI was 30%, the incidence by gestational age category showed a U-shaped distribution, with the highest rates in the oldest (>36 weeks) and youngest (22 weeks to <29 weeks) neonates. The incidence of AKI in the youngest gestational age group was 48%—a finding in line with published single-centre studies. Similarly, the AKI rate in infants born at 36 weeks or older (37%) is consistent with those in other studies of term infants. AKI incidence in the group born at 29 weeks to younger than 36 weeks (18%) has not been reported previously. Our data suggest that infants in this middle group are...
also at risk for AKI, but not to the same extent as at-risk neonates of other ages. One possible explanation might be that these infants are not as critically ill as the lowest age and full-term gestational age groups. Compared with infants in the middle gestational age group, those in the lowest age group were more often outborn, had lower 1 min and 5 min Apgar scores, and had higher rates of respiratory failure, sepsis evaluation, hypoxic ischaemic encephalopathy, necrotising enterocolitis, and maternal vaginal bleeding. Infants in the lowest age category were less likely to be born small for gestational age and less likely to be born to mothers with pre-eclampsia. Infants delivered because of medical maternal conditions, such as pre-eclampsia, tend to be less ill than infants born premature for other reasons (ie, chorioamnionitis). Compared with the middle gestational age group, infants in the full-term group were more likely to be outborn, had higher rates of hypoxic ischaemic encephalopathy, were more often born to mothers with maternal infection, and more likely to be born with meconium-stained fluid.

We used the KDIGO definition adapted for neonates for several reasons. First, an AKI workshop explored this definition and concluded that, although adjustments to the definition might be needed in the future as more data become available, this definition was a reasonable starting point for accrual of epidemiology data on neonatal AKI. Second, because this definition is the most widely accepted definition of AKI in paediatric and adult cohorts, it allowed us to compare our data with other populations. Indeed, the AKI rates we documented in NICU patients are similar to those shown in other populations. AKI is common and is independently associated with clinically significant outcomes. Thus, patients do not just die with AKI, rather, AKI is likely to be a crucial component in the disease process.

The frequency of RRT use in NICUs has not been previously described. Our data show that RRT is used very sparingly in NICUs. Despite the little use, rates of survival in these cohorts are better than those reported in a large paediatric continuous RRT registry, which showed that survival in children weighing less than 5 kg was 44%. Not surprisingly, infants who received RRT had higher mortality than infants in the entire cohort and those with AKI who did not receive RRT. This finding is likely to be due to the increased severity of illness and comorbidities in infants who receive RRT. We assume that without RRT, the survival in patients who received RRT would have been much worse. Having RRT devices available that were specifically designed for neonates could have increased the use of these devices in neonates with AKI, and presumably provided a better chance for survival. The high incidence and mortality ascribed to AKI in NICU is justification for exploration of preventive and therapeutic strategies to minimise the effects of AKI, and implementation of safer RRT devices designed specifically for neonates.

The strengths of our study include the large neonatal cohort, multicentre approach, and successful collaboration between neonatology, paediatric nephrology, and epidemiology experts in neonatal AKI. These factors
enabled a robust analysis that adjusted for potential confounders and included prespecified contemporary definitions. Multidisciplinary collaboration improves the accuracy in interpretation of clinical data and events.

Despite these strengths, we acknowledge several important limitations. First, because this is a retrospective study, we had to rely on serum creatinine and urinary output data available in the medical records; therefore, AKI cases could have been missed. We tried to mitigate this issue by excluding patients with insufficient serum creatinine and urinary output data from outcomes analyses, and did best-case and worst-case sensitivity analyses, which showed that the absence of data for 140 patients in whom AKI status could not be determined did not change our results substantially—ie, the associations with mortality and length of stay remained significant in both scenarios. Second, although the neonatal AKI definition used for this study has been vetted by an expert panel, the definition continues to be empirical. Our findings support use of this definition in the future, although refinement might be necessary. Two groups for which use of this definition requires additional clarification are infants whose serum creatinine does not decline in the first week of life, and infants born with a very high concentrations of serum creatinine due to maternal kidney disease. Future prospective studies should explore how different cutoffs for serum creatinine and urine output, and incorporation of other urinary and serum biomarkers, could improve the ability to reliably define AKI. Third, our inclusion and exclusion criteria did not allow for data collection in all neonates admitted to the NICU during the study period. As described, selection criteria were chosen to identify sick infants who were most likely to have kidney function monitoring, and restrict the number of infants admitted for mild or transient conditions requiring brief periods of supportive care (ie, transient tachypnoea, transient hypoglycaemia, or late prematurity). Given that infants who do not require intravenous fluids rarely have assessments for serum creatinine or quantified urinary output data, restricting these patients reduced the number of infants without adequate data for analysis. Similarly, exclusion of infants who died within the first 48 h of admission is justified because these infants do not always receive full medical support (eg, if the condition is deemed lethal), and 48 h is not ample time to note a rise in serum creatinine and thus be able to assess for AKI. Only 48 (1%) of potential infants were excluded because of death within 48 h. Fourth, despite the large sample size of our study, potential confounders between groups might have been missed. Fifth, we included only two countries outside of North America; thus, this cohort represents mostly North American NICUs. Finally, we did not assess or control for aspects of different health-care systems or seasons (we enrolled infants born from January to March), which might have contributed to variation in antenatal care, mortality rates, and length of stay.

In conclusion, this study provides substantial data depicting the epidemiology of neonatal AKI. We show differences in AKI incidence across gestational age groups and the independent association between AKI and important clinical outcomes. Indeed, our findings are consistent with studies in other critically ill populations, emphasising that the kidney is not just an innocent bystander in critical illness, but rather plays an important role in morbidity and mortality. Initiatives, such as the International Society of Nephrology 0by25 programme, designed to reduce the incidence and sequelae of kidney injury need to also focus on critically ill neonates. Growing evidence on the developmental origin of kidney disease highlights how neonates born premature, small for gestational age, and of low birthweight are at risk of chronic kidney disease because of low nephron number at birth. Low nephron numbers can predispose infants to AKI because they might not have compensatory renal reserve at the time of stress. Furthermore, the effect of AKI on optimal kidney growth in these infants might be substantial. For these reasons, improving understanding of the global burden of neonatal AKI should be a priority for international agencies that advocate for neonates and for populations at risk for kidney disease.

The AWAKEN database will enable the testing of additional questions that cannot be answered in the confines of one publication. Some analyses underway include evaluations of specific AKI risk factors, the effect of fluid balance on outcomes, modifications to the neonatal AKI definition, and the association of AKI with comorbid neonatal conditions. Unfortunately, many questions about neonatal AKI (eg, cause of death, AKI epidemiology during specific events, ability of urine biomarkers to diagnose AKI, and the long-term outcomes after AKI) cannot be addressed in the present cohort because of the retrospective design of the study. To answer these and other questions, partnerships between neonatologists and nephrologists must continue. Carefully planned, adequately powered, prospective studies are greatly needed to further advance our understanding of neonatal AKI. These studies should monitor kidney injury and function data systematically, provide insights about AKI during high-risk events, capture the cause of death, and assess long-term renal recovery. Such studies will provide evidence to create guidelines for neonatologists, paediatricians, and paediatric nephrologists who care for these patients during and after discharge from the NICU.

Contributors

DJA, JGJ, CM, and CSW contributed to the study conception or design. DJA, JGJ, SKS, SW, SR, ASC, RW, CM, JRS, and SS acquired the data. DJA, LJB, and RLG analysed the data. All authors interpreted the data. DJA, JGJ, and LJB drafted the manuscript. All authors critically revised the manuscript for important intellectual content and approved the final version to be published.

www.thelancet.com/child-adolescent   Published online September 7, 2017   http://dx.doi.org/10.1016/S2352-4642(17)30069-X
Neonatal Kidney Collaborative (NKC) collaborators

The following individuals served as collaborators and site investigators for the A WAKEN study. They collaborated in protocol development and review, submission to local institutional review boards, data collection, and participated in drafting or review of the manuscript: David T Selewski and Subrata Sarkar (CS Mott Children’s Hospital, University of Michigan, Ann Arbor, MI, USA); Alison Kent and Jeffery Fleming (Centenary Hospital for Women and Children, Canberra Hospital, Australian National University Medical School, Canberra, ACT, Australia); Carolyn L. Abitol, Marissa DeFreitas, and Shahnaz Duara (Holtz Children’s Hospital, University of Miami, Miami, FL, USA); Jennifer R. Charlton (University of Virginia Children’s Hospital, Charlottesville, VA, USA); Ronnie Guillot, Carl D. Angio, Ayesa Mian, and Erin Rademacher (Golisano Children’s Hospital, University of Rochester, Rochester, NY, USA); Marouan M. Mhanna, Rupesh Raina, and Deepak Kumar (MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, USA); Namasiyavam Ambalavanan (Children’s of Alabama, University of Alabama at Birmingham, Birmingham, AL, USA); Ayse Akan Arikan and Christopher J. Rhee (Texas Children’s Hospital, Baylor College of Medicine, Houston, TX, USA); Stuart L Goldstein and Amy T. Nathan (Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA); Alok Bhutada and Shantanu Rastogi (Maimonides Medical Center, Brooklyn, NY, USA); Elizabeth Bonachea, Susan Ingraham, John Mahan, and Arwa Nada ( Nationwide Children’s Hospital, Columbus, OH, USA); Patrick D Brophy, Tarah T Colaizy, and Jonathan M. Klein (University of Iowa Children’s Hospital, Iowa City, IA, USA); F Sessions Cole and T. Keefe Davis (Washington University, St. Louis, MO, USA); Joshua Dower, Lawrence Milner, and Alexandra Smith (Tufts University School of Medicine, Boston, MA, USA); Mamta Fuloria, Kimberly Reidy, and Frederick J. Kaskel (The Children’s Hospital at Montefiore, Bronx, NY, USA); Jason Gien and Katja M. Gist (University of Colorado, Children’s Hospital Colorado, Aurora, CO, USA); Mina H. Hanna (University of Kentucky, Lexington, KY, USA); Sangreeta Hingorani and Michelle Starr (University of Washington, Seattle Children’s Hospital, Seattle, WA, USA); Catherine Joseph, Tara DuPont, Robin Ohls, and Amy Staples (University of New Mexico Health Sciences Center, Albuquerque, NM, USA); Surinder Khiokhar (Apollo Cradle, Gurgaon, Haryana, India); Sofia Perazzo, Patricio E. Ray, and Mary Reennis (Children’s National Medical Center, George Washington University School of Medicine and the Health Sciences, Washington, DC, USA); Anne Synnes (British Columbia Children’s Hospital, Vancouver, BC, Canada); and Pia Winemark and Michael Zappitelli (Montreal Children’s Hospital, McGill University Health Centre, Montreal, QC, Canada).

Declaration of interests

DJA serves on the speakers’ board for Baxter and the Acute Kidney Injury Foundation, and receives grant funding for studies not related to this manuscript from the National Institutes of Health (NIH)—National Institutes of Diabetes and Digestive and Kidney Diseases (grant number R01 DK013608) and NIH—Food and Drug Administration (R01 FD005992). JQG is supported by the University of Iowa Institute for Clinical and Translational Sciences (NIH U54TR001356). JQG is on the speaker’s bureau and acts as a consultant for Alexion Pharmaceuticals. RW is supported by the Department of Pediatrics at Stony Brook Children’s Hospital. A WAKEN investigators at the Canberra Hospital were supported by the Canberra Hospital Private Practice fund, and investigators at University of Virginia Children’s Hospital were supported by a 100 Women Who Care Grant. All other authors declare no competing interests.

Acknowledgments

Cincinnati Children’s Hospital Center for Acute Care Nephrology provided funding to create and maintain the A WAKEN Medidata Rave electronic database. The Pediatric and Infant Center for Acute Nephrology (PICAN) provided support for web meetings, for the NKC steering committee annual meeting at the University of Alabama at Birmingham (UAB), and support for some of the A WAKEN investigators at UAB (LB, RLG). PICAN is part of the Department of Pediatrics at the UAB, and is funded by the Department of Pediatrics at Children’s of Alabama, UAB School of Medicine, and UAB’s Center for Clinical and Translational Sciences (NIH grant UL1TR000147). The A WAKEN study at the University of New Mexico was supported by the Clinical and Translational Science Center (NIH grant UL1TR000449) and by the University of Iowa Institute for Clinical and Translational Science (U54TR001356). We thank Emma Perez-Costas (Department of Pediatrics, UAB, Birmingham, AL, USA) for help with technical editing and proofreading of this manuscript. We also thank the following clinical research personnel and colleagues for their involvement in A WAKEN: Ana Paljian and Michael Pizzii (Montreal Children’s Hospital, McGill University Health Centre, Montreal, QC, Canada); Julia Wrona (University of Colorado, Children’s Hospital Colorado, Aurora, CO, USA); Melissa Bowman (University of Rochester, Rochester, NY, USA); Teresa Cano, Marta G. Galarza, Wendy Glaberson, and Denise Cristina Pereja Valarezo (Holtz Children’s Hospital, University of Miami, Miami, FL, USA); Sarah Cashman (University of Iowa Children’s Hospital, Iowa City, IA, USA); Alanna DeMelo (British Columbia Children’s Hospital, Vancouver, BC, Canada); Lynn Dill (University of Alabama at Birmingham, Birmingham, AL, USA); Ellen Guthrie (MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, USA); Nicholas J. Harris and Susan M. Hieber (CS Mott Children’s Hospital, University of Michigan, Ann Arbor, MI, USA); Judd Jacobs and Tara Terrell (Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA); Nilima Jawale (Maimonides Medical Center, Brooklyn, NY, USA); Emily Kane (Australian National University, Canberra, ACT, Australia); Patricia Mele (Stony Brook Children’s Hospital, Stony Brook, NY, USA); Charles R. Ney (Texas Children’s Hospital, Baylor College of Medicine, Houston, TX, USA); Emily Pao (University of Washington, Seattle Children’s Hospital, Seattle, WA, USA); and Leslie Wältner (Washington University, St. Louis, MO, USA).

References

1. Taylor M, Carmona F, Thiaaarajaran RR, et al. Mild postoperative acute kidney injury and outcomes after surgery for congenital heart disease. *J Thorac Cardiovasc Surg* 2013; 146: 146–52.
2. Blinder JJ, Goldstein SL, Lee VV, et al. Congenital heart surgery in infants: effects of acute kidney injury on outcomes. *J Thorac Cardiovasc Surg* 2012; 143: 568–74.
3. Wong JH, Selewski DT, Yu S, et al. Severe acute kidney injury following stage I Norwood palliation: effect on outcomes and risk of severe acute kidney injury at subsequent surgical stages. *Pediatr Crit Care Med* 2016; 17: 615–23.
4. Di Nardo M, Facirella A, Ricci Z, et al. Impact of severe sepsis on serum and urinary biomarkers of acute kidney injury in critically ill children: an observational study. *Blood Purif* 2013; 35: 172–76.
5. Mathur NB, Agarwal HS, Maria A. Acute renal failure in neonatal sepsis. *Indian J Pediatr* 2006; 73: 499–502.
6. Alaro D, Bashur A, Mskouk R, Wamazana L. Prevalence and outcomes of acute kidney injury in term neonates with perinatal asphyxia. *Afr Health Sci* 2014; 14: 682–88.
7. Selewski DT, Jordan DK, Askennazi DJ, Dehert RE, Sarkar S. Acute kidney injury in asphyxiated newborns treated with therapeutic hypothermia. *J Pediatr* 2013; 162: 725–29.
8. Askennazi DJ, Koralik R, Hundley HE, Montesanti A, Patil N, Ambalavanan N. Fluid overload and mortality are associated with acute kidney injury in sick near-term/term neonate. *Pediatr Nephrol* 2013; 28: 661–66.
9. Askennazi DJ, Ambalavanan N, Hamiton K, et al. Acute kidney injury and renal replacement therapy independently predict mortality in neonatal and pediatric noncardiac patients on extracorporeal membrane oxygenation. *Pediatr Crit Care Med* 2012; 13: 303–11.
10. Fleming GM, Sahay R, Zappitelli M, et al. The incidence of acute kidney injury and its effect on neonatal and pediatric extracorporeal membrane oxygenation outcomes: a multicenter report from the Pediatric Intensive Care During Extracorporeal Membrane Oxygenation Study Group. *Pediatr Crit Care Med* 2016; 17: 1157–69.
11. Koralik R, Ambalavanan N, Levitan EB, McGowin G, Goldstein S, Askennazi D. Acute kidney injury reduces survival in very low birth weight infants. *Pediatr Res* 2011; 69: 354–58.
12. Carron BK, Swanson JR, Rhone ET, Charlton JR. Recognition and reporting of AKI in very low birth weight infants. *Clin J Am Soc Nephrol* 2014; 9: 2036–43.
13. Wisvanathan S, Manyan B, Azhioukov T, Mhanna MJ. Risk factors associated with acute kidney injury in extremely low birth weight (ELBW) infants. *Pediatr Nephrol* 2012; 27: 303–11.
Stojanovic V, Barisic N, Milanovic B, Doronjski A. Acute kidney injury in preterm infants admitted to a neonatal intensive care unit. *Pediatr Nephrol* 2014; 29: 2213–20.

Weintraub AS, Connors J, Carey A, Blanco V, Green RS. The spectrum of onset of acute kidney injury in premature infants less than 30 weeks gestation. *J Perinatol* 2016; 36: 67–80.

Jetton JG, Guillet R, Askenazi DJ, et al. Assessment of worldwide acute kidney injury epidemiology in neonates: design of a retrospective cohort study. *Front Pediatr* 2016; 4: 68.

Kellum JA, Lameire N, KDIGO AKI Guideline Work Group. Diagnostics, evaluation, and management of acute kidney injury: a KDIGO summary (part I). *Crit Care* 2013; 17: 204.

Jetton JG, Askenazi DJ. Acute kidney injury in the neonate. *Clin Perinatol* 2014; 41: 487–502.

Stoops C, Sims B, Griffin R, Askenazi DJ. Neonatal acute kidney injury and the risk of intraventricular hemorrhage in the very low birth weight infant. *Neonatology* 2016; 110: 307–32.

Askenazi D, Patil NR, Ambalavanan N, et al. Acute kidney injury is associated with bronchopulmonary dysplasia/mortality in premature infants. *Pediatr Nephrol* 2015; 30: 1511–18.

Sarkar S, Askenazi DJ, Jordan BK, et al. Relationship between acute kidney injury and brain MRI findings in asphyxiated newborns after therapeutic hypothermia. *Pediatr Res* 2014; 75: 431–35.

Parry G, Tucker J, Tarnow-Mordi W; UK Neonatal Staffing Study Collaborative. CRIB II: an update of the clinical risk index for babies score. *Lancet* 2003; 361: 1789–91.

Kaddourah A, Basu RK, Bagshaw SM, Goldstein SI, AWARE Investigators. Epidemiology of acute kidney injury in critically ill children and young adults. *N Engl J Med* 2017; 376: 11–20.

Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. *Intensive Care Med* 2015; 41: 1413–23.

Zappittelli M, Ambalavanan N, Askenazi DJ, et al. Developing a neonatal acute kidney injury definition. A report form the NIDDK neonatal AKI workshop. *Pediatr Res* 2017; published online July 12. DOI:10.1038/pr.2017.116.

Bezerra CT, Vaz Cunha LC, Liborio AB. Defining reduced urine output in neonatal ICU: importance for mortality and acute kidney injury classification. *Nephrol Dial Transplant* 2013; 28: 901–09.

Askenazi DJ, Goldstein SI, Koralkar R, et al. Continuous renal replacement therapy for children ≤30 kg: a report from the prospective pediatric continuous renal replacement therapy registry. *J Pediatr* 2013; 162: 587–92.

Ronco C, Garzotto F, Brendolan A, et al. Continuous renal replacement therapy in neonates and small infants: development and first-in human use of a miniaturized machine (CARPEDIEM). *Lancet* 2014; 383: 1807–13.

Mehta RL, Burdmann EA, Cerda J, et al. Recognition and management of acute kidney injury in the International Society of Nephrology 0by25 global snapshot: a multinational cross-sectional study. *Lancet* 2016; 387: 2017–25.

Luyckx VA, Perico N, Somaschini M, et al. A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group. *Lancet* 2017; 390: 424–28.